Regulatory matrix
91 published regulatory records. Each cites an official source and the date it was checked. A regulatory status says what one regulator recorded for one scope. It is not evidence of efficacy or safety, and one jurisdiction’s action does not apply in another. Pairs marked “No published record” mean only that WPF has published nothing for that jurisdiction. They do not mean no regulatory action exists or that a review is scheduled. Product or formulation is shown as “Not recorded” because the record does not capture it. The action label comes from the linked official source, not from the jurisdiction name.
8 rows
| Peptide | Jurisdiction | Regulator | Product or formulation | Scope | Action | Linked source | Date checked |
|---|---|---|---|---|---|---|---|
| Semaglutide | European Union (EMA) | EMA | Not recorded | Semaglutide is centrally authorised in the European Union in product-specific forms: Ozempic and Rybelsus for defined type 2 diabetes populations, and Wegovy for weight management in defined adults and adolescents. The applicable population, formulation, dose, contraindications, and current product information remain controlling. | Approval recorded | EMA EPARs — Wegovy, Ozempic and RybelsusLinked source: www.ema.europa.eu | 2026-09-08 |
| Semaglutide | United States (FDA) | FDA | Not recorded | Current FDA labeling for Wegovy identifies semaglutide formulations for defined cardiovascular-risk reduction and chronic weight-reduction populations; Wegovy injection is also approved for defined adults with noncirrhotic MASH and moderate-to-advanced fibrosis under accelerated approval. Product, formulation, age, comorbidity, and indication restrictions apply. | Approval recorded | FDA Wegovy Prescribing Information, revised June 2026Linked source: www.accessdata.fda.gov | 2026-09-08 |
| Semaglutide | United Kingdom | MHRA | Not recorded | Not recorded | No published record | — | — |
| Semaglutide | Canada | Health Canada | Not recorded | Not recorded | No published record | — | — |
| Semaglutide | Australia | TGA | Not recorded | Not recorded | No published record | — | — |
| Semaglutide | Japan | PMDA / MHLW | Not recorded | Not recorded | No published record | — | — |
| Semaglutide | China | NMPA | Not recorded | Not recorded | No published record | — | — |
| Semaglutide | Sport (WADA) | WADA | Not recorded | Not recorded | No published record | — | — |